Pancreatic alpha-cell function in idiopathic reactive hypoglycemia

An extended minimal model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect

Loss of insulin sensitivity, α- and β-cell dysfunction, and impairment in incretin effect have all been implicated in the pathophysiology of type 2 diabetes (T2D). Parsimonious mathematical models are useful in quantifying parameters related to the pathophysiology of T2D. Here, we extend the minimum model developed to describe the glucose-insulin-glucagon dynamics in the isoglycemic intravenous glucose infusion (IIGI) experiment to the oral glucose tolerance test (OGTT). The extended model describes glucose and hormone dynamics in OGTT including the contribution of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), to insulin secretion. A new function describing glucose arrival from the gut is introduced. The model is fitted to OGTT data from eight individuals with T2D and eight weight-matched controls (CS) without diabetes to obtain parameters related to insulin sensitivity, β- and α-cell function. The parameters, i.e., measures of insulin sensitivity, a1, suppression of glucagon secretion, k1, magnitude of glucagon secretion, γ2, and incretin-dependent insulin secretion, γ3, were found to be different between CS and T2D with P values < 0.002, <0.017, <0.009, <0.004, respectively. A new rubric for estimating the incretin effect directly from modeling the OGTT is presented. The average incretin effect correlated well with the experimentally determined incretin effect with a Spearman rank test correlation coefficient of 0.67 (P < 0.012). The average incretin effect was found to be different between CS and T2D (P < 0.032). The developed model is shown to be effective in quantifying the factors relevant to T2D pathophysiology.NEW & NOTEWORTHY A new extended model of oral glucose tolerance test (OGTT) has been developed that includes glucagon dynamics and incretin contribution to insulin secretion. The model allows the estimation of parameters related to α- and β-cell dysfunction, insulin sensitivity, and incretin action. A new function describing the influx of glucose from the gut has been introduced. A new rubric for estimating the incretin effect directly from the OGTT experiment has been developed. The effect of glucose dose was also investigated.

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment

Type 2 diabetes (T2D) is a pathophysiology that is characterized by insulin resistance, beta- and alpha-cell dysfunction. Mathematical models of various glucose challenge experiments have been developed to quantify the contribution of insulin and beta-cell dysfunction to the pathophysiology of T2D. There is a need for effective extended models that also capture the impact of alpha-cell dysregulation on T2D. In this paper a delay differential equation-based model is developed to describe the coupled glucose-insulin-glucagon dynamics in the isoglycemic intravenous glucose infusion (IIGI) experiment. As the glucose profile in IIGI is tailored to match that of a corresponding oral glucose tolerance test (OGTT), it provides a perfect method for studying hormone responses that are in the normal physiological domain and without the confounding effect of incretins and other gut mediated factors. The model was fit to IIGI data from individuals with and without T2D. Parameters related to glucagon action, suppression, and secretion as well as measures of insulin sensitivity, and glucose stimulated response were determined simultaneously. Significant impairment in glucose dependent glucagon suppression was observed in patients with T2D (duration of T2D: 8 (6–36) months) relative to weight matched control subjects (CS) without diabetes (k1 (mM)−1: 0.16 ± 0.015 (T2D, n = 7); 0.26 ± 0.047 (CS, n = 7)). Insulin action was significantly lower in patients with T2D (a1 (10 pM min)−1: 0.000084 ± 0.0000075 (T2D); 0.00052 ± 0.00015 (CS)) and the Hill coefficient in the equation for glucose dependent insulin response was found to be significantly different in T2D patients relative to CS (h: 1.4 ± 0.15; 1.9 ± 0.14). Trends in parameters with respect to fasting plasma glucose, HbA1c and 2-h glucose values are also presented. Significantly, a negative linear relationship is observed between the glucagon suppression parameter, k1, and the three markers for diabetes and is thus indicative of the role of glucagon in exacerbating the pathophysiology of diabetes (Spearman Rank Correlation: (n = 12; (−0.79, 0.002), (−0.73,.007), (−0.86,.0003)) respectively).

Glucagon responses to glucose challenge in patients with idiopathic postprandial syndrome

BACKGROUND

Postprandial syndrome is characterized by hunger, weakness and anxiety neurosis occurring after meals. Although abnormal glucagon response has been suggested, inaccuracies of the conventional glucagon measurement method have prevented from precise analysis. Recently, a more reliable dual-antibody sandwich enzyme-linked immunosorbent assay for glucagon has been developed.

METHODS

We conducted a 75 g oral glucose tolerance test (OGTT) extending to 4 hours in 14 patients with idiopathic postprandial syndrome. In addition to blood glucose and insulin, we have measured glucagon concentrations using the novel method and analyzed retrospectively.

RESULTS

Median (lower quartile, upper quartile) of age and BMI were 40 years old (30, 49) and 24.9 (23.1, 26.2), respectively. The OGTT revealed that one patient had a diabetic pattern, and two were glucose intolerant. Fasting insulin was 7.6 μU/mL (6.8, 8.8) and reached 73.7 (54.3, 82.6) at 30 min. Insulin remained elevated until 180 min. The fasting glucagon was 21.1 pg/mL (16.1, 33.8), falling at 60 min to a nadir of 6.9 (3.5, 10.3), one-third of the baseline, then remaining suppressed until 180 min. Furthermore, we have found that two types of glucagon dynamics: one is lower fasting glucagon with further suppression and the other is normal or higher fasting glucagon with subsequent big drop.

CONCLUSIONS

These data suggest that glucagon suppression is stronger in patients with idiopathic postprandial syndrome than in normal subjects previously reported. The present data will contribute to further understanding and future research of this syndrome.

The nature of the control of blood glucose in those with poorer glucose tolerance influences mood and cognition

The ability to control the levels of blood glucose was related to mood and cognition. 155 adults, aged 45-85 years, without a diagnosis of diabetes, were given an oral glucose tolerance test and cognitive tests. Participants were classified according to age (41-60/61-85 years), whether they had better or poorer glucose tolerance and whether blood glucose did or did not fall below baseline values. There were two main findings. Those with poorer glucose tolerance forgot more words and had slower decision times, but only if 61 years or older. Secondly as there are reports in animal studies that inducing low levels of blood glucose values benefited cognitive performance, for the first time in humans, individual differences in the tendency to develop low levels of blood glucose were considered. In those with poor glucose tolerance a tendency for blood glucose to fall below baseline values was associated with better mood and faster working memory.

Post prandial plasma glucose level less than the fasting level in otherwise healthy individuals during routine screening

During routine screening, some otherwise healthy individuals who showed remarkably lower post prandial (at 2 hour) plasma glucose without any symptom were subjected to extended glucose tolerance test and a few of them to extended post meal tolerance test as well. It was observed that post prandial (at 2 hour) plasma glucose after glucose administration was significantly lower than the fasting level (p<0.05-p<0.001). However, post prandial plasma glucose at 2 hour after their usual meal exhibited a significantly higher level than the fasting and post glucose level (p<0.05-p<0.001). Glucose appears to be a stronger agent than the more natural mixed meal in these individuals in causing post prandial lowering of plasma glucose. Hence, these individuals are to be evaluated with their usual meals before considering further investigations. Like upper limit, there is the need to have a consensus lower limit of reference interval of blood glucose level.

Idiopathic reactive hypoglycaemia - prevalence and effect of fibre on glucose excursions

BACKGROUND

Idiopathic reactive hypoglycaemia (IRH) is a condition characterized by aggravated postprandial glucose excursions in otherwise healthy individuals. We investigated its prevalence and the impact of fibre diet supplementation.

METHODS

First, IRH prevalence was assessed in 362 subjects without a diagnosis of abnormal glucose metabolism through an oral glucose tolerance test (OGTT). IRH was defined by 1 h- or 2 h-glucose ≤3.9 mmol/L or 1 h- or 2 h-glucose < fasting glucose. Second, in a cross-over trial we evaluated effects of 2 weeks with, and without, 20 g fibre (fructose- oligosaccharides) diet supplementation in subjects with IRH. At the end of each 2-week cycle we analysed fasting biomarker levels and conducted a 4 h-OGTT.

RESULTS

IRH was found in 12.4% and a normal glucose tolerance in 56.4% of the participants. The IRH group was characterized by higher fasting (5.3 vs. 5.2 mmol/L, p < 0.05) but lower 2 h- (4.4 vs. 6.5 mmol/L, p < 0.01) glucose levels, whereas age (68 ± 10 vs. 70 ± 9 years) and BMI (24.7 ± 3.3 vs 25.0 ± 3.5 kg/m(2)) were similar. The 2-week fibre diet-supplementation (n = 12, age 56 ± 8 years, 6 females, BMI 25.0 ± 2.9 kg/m(2)) improved both the reactive glucose pattern during the 4 h-OGTT (significantly increased late-onset glucose nadirs and reduced the frequency of glucose ≤3.9 mmol/L [21 to 11, p = 0.04]) and reduced fasting plasma glucose (5.4 ± 0.6 to 5.1 ± 0.5 [p < 0.05]) and total cholesterol (5.3 ± 1.1 to 4.9 ± 1.1 mmol/L [p < 0.04]).

CONCLUSIONS

A reactive glucose pattern following intake of a high glycaemic load is relatively prevalent and this phenomenon could be modulated by dietary fibre supplementation.